Amylyx Pharmaceuticals Inc (AMLX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joshua B. Cohen
Employees:
220
43 THORNDIKE STREET, CAMBRIDGE, MA 02141
617-683-0917

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Data derived from most recent annual or quarterly report
Market Cap 2.368 Billion Shares Outstanding57.86 Million Avg 30-day Volume 843.528 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA0
Price to Book Value11.4402 Operating Margin0.0 Enterprise Value1.485 Billion
Current Ratio5.275 EPS Growth0 Quick Ratio4.985
1 Yr BETA 1.0456 52-week High/Low 41.25 / 6.51 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score24.9426 Free Cash Flow to Firm 0
Earnings Report2023-03-29

Are you looking for this stock instead?

View SEC Filings from AMLX instead.

View recent insider trading info

Amylyx Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AMLX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMLX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 5: filed on 2023-01-11 by MORNINGSIDE VENTURE INVESTMENTS LTD
  • 4: filed on 2023-01-10 by YERAMIAN PATRICK D
  • 4: filed on 2023-01-10 by COHEN JOSHUA B
  • 4: filed on 2023-01-10 by FRATES JAMES M
  • 4: filed on 2023-01-10 by OLINGER MARGARET
  • 4: filed on 2023-01-10 by KLEE JUSTIN B.
  • 4: filed on 2022-07-08 by ALS INVEST 1 B.V.
  • 4: filed on 2022-06-10 by FONTEYNE PAUL R.
  • 4: filed on 2022-06-10 by MILNE GEORGE M JR
  • 4: filed on 2022-06-10 by CHENG ISAAC

    • Events (8k)

  • 8-K: filed on 2022-12-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-09:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    19 Thousand total shares from 10 transactions

    Exercise Derivative Conversion (M)

    5 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FRATES JAMES M CHIEF FINANCIAL OFFICER

    • Officer
    		 68,840 2023-01-06 3

    YERAMIAN PATRICK D CHIEF MEDICAL OFFICER

    • Officer
    		 409,227 2023-01-06 1

    KLEE JUSTIN B. CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 5,787,080 2023-01-06 2

    COHEN JOSHUA B CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 5,787,080 2023-01-06 2

    OLINGER MARGARET CHIEF COMMERCIAL OFFICER

    • Officer
    		 429,453 2023-01-06 1

    MORNINGSIDE VENTURE INVESTMENTS LTD

    • 10% Owner
    		 7,680,598 2022-12-31 1

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    DRAGSA 96 LLC

    • 10% Owner
    		 5,770,536 2022-09-08 1

    ALS INVEST 1 B.V.

    • 10% Owner
    		 5,895,280 2022-07-06 1

    MILNE GEORGE M JR

    • Director
    		 19,000 2022-06-09 1

    QUIMI DAPHNE

    • Director
    		 19,000 2022-06-09 1

    FONTEYNE PAUL R.

    • Director
    		 19,000 2022-06-09 1

    CHENG ISAAC

    • Director
    		 19,000 2022-06-09 1

    MAZZARIELLO GINA CHIEF LEGAL OFFICER

    • Officer
    		 223,000 2022-02-22 2

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    		 0 2022-01-11 1

    DRAGSA 96 LLC

    • 10% Owner
    		 2,300,000 2022-01-11 0

    MORNINGSIDE VENTURE INVESTMENTS LTD

    MVIL, LLC

    • 10% Owner
    		 21,094,458 2022-01-06 1

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    KLEE JUSTIN B. - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    		2023-01-10 19:12:48 -0500 2023-01-06 S 4,122 $36.08 a 2,894,463 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    KLEE JUSTIN B. - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    		2023-01-10 19:12:48 -0500 2023-01-06 S 1,846 $36.79 a 2,892,617 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    OLINGER MARGARET - Officer CHIEF COMMERCIAL OFFICER

    		2023-01-10 19:19:15 -0500 2023-01-06 S 1,660 $36.08 a 215,098 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    OLINGER MARGARET - Officer CHIEF COMMERCIAL OFFICER

    		2023-01-10 19:19:15 -0500 2023-01-06 S 743 $36.79 a 214,355 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    FRATES JAMES M - Officer CHIEF FINANCIAL OFFICER

    		2023-01-10 19:20:38 -0500 2023-01-06 S 1,836 $36.08 a 34,831 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    FRATES JAMES M - Officer CHIEF FINANCIAL OFFICER

    		2023-01-10 19:20:38 -0500 2023-01-06 S 822 $36.79 a 34,009 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    		2023-01-10 19:20:58 -0500 2023-01-06 S 4,122 $36.08 a 2,894,463 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER

    		2023-01-10 19:20:58 -0500 2023-01-06 S 1,846 $36.79 a 2,892,617 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    YERAMIAN PATRICK D - Officer CHIEF MEDICAL OFFICER

    		2023-01-10 19:22:45 -0500 2023-01-06 S 1,405 $36.08 a 204,928 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    YERAMIAN PATRICK D - Officer CHIEF MEDICAL OFFICER

    		2023-01-10 19:22:45 -0500 2023-01-06 S 629 $36.79 a 204,299 direct yes 1.6204 -5.1634 2.9662 3 -5.1634 6

    FRATES JAMES M - Officer CHIEF FINANCIAL OFFICER

    		2023-01-04 21:33:55 -0500 2022-12-30 M 5,000 $6.88 a 36,667 direct 3.9921 4.0202 4.0202 6 0.0 1

    FRATES JAMES M - Officer CHIEF FINANCIAL OFFICER

    		2023-01-04 21:33:55 -0500 2022-12-30 M 5,000 d 447,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 22:15:03 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 21:45:04 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 21:15:04 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 20:45:03 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 20:15:04 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 19:45:03 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 19:15:03 UTC 3.8936 0.4264 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 18:45:04 UTC 3.902 0.418 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 18:15:03 UTC 3.902 0.418 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 17:45:03 UTC 3.902 0.418 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 17:15:04 UTC 3.902 0.418 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 16:45:03 UTC 3.5655 0.7545 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 16:15:03 UTC 3.5655 0.7545 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 15:45:03 UTC 3.5655 0.7545 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 15:15:04 UTC 3.5655 0.7545 650000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 14:45:04 UTC 3.5655 0.7545 650000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 14:15:03 UTC 3.5655 0.7545 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 13:45:03 UTC 3.9101 0.4099 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 13:15:03 UTC 3.9101 0.4099 1100000
    AMYLYX PHARMACEUTICALS INC AMLX 2023-01-27 12:45:03 UTC 3.9101 0.4099 1100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AMLX -12500.0 shares, $-351875.0 2022-09-30 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2022-11-11 2022-10-12 P $1,001-$15,000

    Elevate your investments